Tier 3 — preclinical

Prophylactic Effects of Betaine on Depression and Anxiety Behaviors in Mice with Dextran Sulfate Sodium-Induced Colitis

Wenjia Liu, Xiaolin Zhong, Yan Yi, Lihua Xie, Wenyan Zhou, Wenyu Cao, Ling Chen
Journal of agricultural and food chemistry 2024 72(38):21041-21051

Bibliography

PubMed
PMID 39276097
DOI
10.1021/acs.jafc.4c05547
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignExperimental animal and/or laboratory research
ModelDSS-treated mice
SampleExperiment-specific biological replicates and model groups; see original methods
InterventionBetaine in a chemically induced colitis model
DurationAcute DSS challenge with prophylactic experimental treatment
EndpointsColitis; Behavior; Mitochondrial stress

What the study showed, in plain terms

Published in 2024, this source examined preclinical aging, brain and metabolic mechanisms. Design: Experimental animal and/or laboratory research. Sample/model: Experiment-specific biological replicates and model groups; see original methods. The exposure or intervention was Betaine in a chemically induced colitis model. Follow-up or treatment period: Acute DSS challenge with prophylactic experimental treatment.

Betaine improved colonic and selected anxiety/depression-like measures, with proposed mitochondrial and cGAS-STING mechanisms.

Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Betaine improved colonic and selected anxiety/depression-like measures, with proposed mitochondrial and cGAS-STING mechanisms.
  • The recorded outcome domains were Colitis; Behavior; Mitochondrial stress.
  • The result applies to the tested exposure: Betaine in a chemically induced colitis model; Acute DSS challenge with prophylactic experimental treatment.

What this study can and cannot tell us

  • Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 3
Systematic profiling reveals betaine as an exercise mimetic for geroprotection
Lingling Geng et al. · Cell · 2025
Tier 4
Betaine and aging: A narrative review of findings, possible mechanisms, research perspectives, and practical recommendations
Emilia Zawieja et al. · Ageing research reviews · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology